September 2022

The United States Preventive Services Task Force (USPSTF) finalized its statement on the use of statins for primary prevention of cardiovascular disease (CVD) last week, polarizing the medical community like a partisan bill on the Senate floor.

The USPSTF based its recommendation on 23 clinical trials and three observational studies that assessed the head-to-head use of a statin with either placebo or no statin on CVD risk. True to brand, the task force erred on the side of caution and recommended a conservative approach.

Read more »